Does tirzepatide cause headaches? Headaches can happen during treatment, but the largest obesity trial found almost the same rate with placebo. Neither Zepbound nor Mounjaro lists headache in its common side-effect table. That doesn't make a new headache imaginary or explain its cause.
Fluid loss, missed meals, caffeine changes, and low blood sugar with certain diabetes medicines are possibilities a provider considers. Sudden severe pain or a headache with new vision changes needs urgent assessment.
Does tirzepatide cause headaches in trials?
About 7 in 100 participants reported headaches in SURMOUNT-1, whether they received tirzepatide or placebo, an injection without the active medicine. This 72-week trial enrolled 2,539 adults with obesity or overweight and a weight-related condition, without diabetes.
Table 4 of Jastreboff and colleagues' New England Journal of Medicine paper, 2022 gives the exact counts:
| SURMOUNT-1 group | Participants reporting headache | Percentage |
|---|---|---|
| Tirzepatide 5 mg | 41 of 630 | 6.5% |
| Tirzepatide 10 mg | 43 of 636 | 6.8% |
| Tirzepatide 15 mg | 41 of 630 | 6.5% |
| Placebo | 42 of 643 | 6.5% |
These are symptoms reported during treatment, not proof that the drug caused every event. The near-matching rates don't show a clear headache increase in this trial. They also can't rule out a medication-related headache in one person.
As of October 1, 2026, the day this article was written, the current Zepbound label and Mounjaro label both carry “Revised: 08/2026.” Neither has a headache row in its section 6 common-reaction table, so neither supplies a headache-versus-placebo percentage there.
Those tables select reactions that meet frequency thresholds and occur more often than with placebo. An absent row doesn't mean no headaches occurred. Both medication guides mention headache as a possible symptom of low blood sugar.
In SURPASS-2, published in the New England Journal of Medicine in 2021, 1,879 adults with type 2 diabetes were followed for 40 weeks. Its main safety table has no headache row. The common problems were digestive: nausea affected 17%–22% on tirzepatide, diarrhea 13%–16%, and vomiting 6%–10%. These are diabetes-trial figures, separate from SURMOUNT-1.
Fluid loss can be part of the headache
Dehydration means the body has too little fluid. Vomiting and diarrhea can remove fluid, while nausea can make drinking harder. MedlinePlus lists headache among dehydration symptoms, alongside thirst, dry mouth, darker urine, and reduced urination.
The tirzepatide labels connect these stomach symptoms with a more serious concern. Their warning describes “gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea.” That fluid loss can lead to acute kidney injury, a sudden decline in kidney function.
The warning supports asking about fluid intake and stomach symptoms. It doesn't establish dehydration as the cause of most tirzepatide headaches. A headache without vomiting or diarrhea still deserves its own explanation.
Low blood sugar: the other medicines matter
Hypoglycemia means low blood sugar. Headache can be one symptom, but shaking, sweating, confusion, hunger, or a fast heartbeat may also occur. The label warns that the risk increases with insulin or sulfonylureas, diabetes medicines that prompt insulin release.
A headache alone cannot establish a low glucose reading. A clinician considers symptoms, measurements, and the complete medication list together. The separate guide to tirzepatide and low blood sugar explains how the risk changes across treatment settings.
Missed meals and a changed coffee routine
Reduced appetite can turn eating less into skipping meals. The International Headache Society recognizes headache attributed to fasting, which can occur without low blood sugar. A missed meal and a measured glucose low are different findings.
Caffeine changes are another possible contributor. The Society's caffeine-withdrawal classification describes headaches after regular caffeine intake is interrupted or delayed. Someone who stops their usual coffee because of nausea may have changed two things at once.
Neither classification proves what caused an individual headache after treatment began. Food, fluid, and caffeine patterns simply give the provider useful clues. Our tirzepatide and caffeine guide covers the broader coffee question.
Tirzepatide and migraine: a new, small report
Migraine is a recurring headache disorder that can bring nausea and sensitivity to light or sound. It is different from an occasional headache after a shot.
As of October 1, 2026, the day this article was written, a case series first published July 6, 2026, in Headache describes fewer migraines in two people after tirzepatide began. A case series is a report of individual patients, without a comparison group.
Both people also lost weight, and headache estimates depended on their recall rather than daily diaries. One used a compounded formulation. Those observations cannot establish a migraine-prevention benefit for tirzepatide or a particular compounded preparation. Neither brand label lists migraine treatment as a use.
When a headache needs urgent care
A sudden, explosive headache or the worst headache someone has experienced warrants emergency assessment. Headache with new vision changes, weakness, trouble speaking, confusion, or fever and a stiff neck also needs urgent care. These are general headache danger signs, regardless of when medication started.
Inability to keep fluids down, very little urine, fainting, or confusion also calls for urgent assessment. A persistent headache or a changed pattern deserves clinical review even without those emergency signs.
Would semaglutide avoid the problem?
A different medicine doesn't guarantee a headache-free course. Both tirzepatide and semaglutide caused digestive symptoms in SURPASS-2, and that study did not test switching people because of headaches.
The semaglutide headache guide covers that medicine's trial rates and migraine research. A provider weighs the cause of the headache and the whole treatment history when considering either medicine.
What belongs in the prescriber conversation
Useful details include when the headache started, how long it lasts, whether it resembles previous headaches, and what changed around that time. Food and fluid intake, caffeine, stomach symptoms, other medicines, and available glucose readings all matter. The prescriber decides whether an examination or testing is needed and sets the treatment plan.
A compounded medication is prepared by a pharmacy for an individual prescription. Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. FDA explains that compounded drugs do not undergo its review for safety, effectiveness, or quality before marketing. Brand-trial percentages cannot establish the exact headache rate for a compounded formulation.
A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor. At Promise, a licensed U.S. provider reviews every request, and not everyone qualifies.
